OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - MODERNA | Market Closed - Deutsche Boerse AG 20:39:22 17/05/2024 BST | ||
| 7.03 EUR | -0.57% |
|
| Current month | +35.45% | ||
| 1 month | +56.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 7.03 | -0.57% |
| 16/05/24 | 7.07 | +5.52% |
| 15/05/24 | 6.7 | +0.90% |
| 14/05/24 | 6.64 | +2.00% |
| 13/05/24 | 6.51 | +12.82% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 08:39 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SB17UF |
| ISIN | DE000SB17UF6 |
| Date issued | 24/06/2020 |
| Strike | 55.86 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 38.84 € |
|---|---|
| Lowest since issue | 1.04 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.9
USD
Average target price
138.5
USD
Spread / Average Target
+4.22%
- Stock Market
- Certificates
- Certificat
